Scaling Up Production of Brazzein, a Novel Sweetener, with GreenLab

To scale up its production of brazzein, GreenLab will leverage its proprietary technology to grow proteins inside corn kernels, optimizing its process with Ginkgo’s Plant Trait Services, Protein Services, and Deployment Capabilities


We’re thrilled about our latest collaboration with GreenLab, to enable the commercial scale production of brazzein, a sweet-tasting protein found in the fruit of the native West African Oubli plant. Ginkgo and GreenLab have previously partnered on a project to develop an enzyme for GreenLab’s PFAS degradation application.

The global sugar replacement market is growing due to increased consumer demand. Sugar substitutes can help manage obesity, but some artificial sweeteners have been linked to various health issues including heart disease. Novel sweeteners — like brazzein, which has a sweetness factor up to 2,000 times greater than sucrose — can be used as natural substitutes for sugar in products across the food and beverage industry.

GreenLab hopes to revolutionize the sweetener industry with brazzein. Its proprietary technology allows it to grow enzymes and other proteins inside of corn kernels. By producing proteins in a cultivated crop, GreenLab can readily scale production across acres of cornfields, with little additional up-front capital and infrastructure. After the protein of interest is extracted from the kernel with minimal waste, most of the corn used will then proceed along the existing value chain, including food, feed or fuel. Thanks to its proprietary technology, GreenLab currently has two transformative enzymes in commercial production, including manganese peroxidase and laccase, and has already successfully grown corn containing brazzein.

GreenLab is leveraging Ginkgo’s capabilities to scale up its production of brazzein in three ways:

  • One, using Ginkgo Plant Trait Services to improve GreenLab’s expression of brazzein in the corn kernel to achieve economically-competitive levels.
  • Two, using Ginkgo Protein Services to express brazzein in a microbial chassis via precision fermentation.
  • And three, using Ginkgo Deployment Capabilities to develop downstream processes to purify brazzein from both the corn kernel and fermentation broth.

By pursuing these pathways to brazzein production, GreenLab intends to be the preeminent supplier of brazzein to food and beverage companies, all while reducing market and technical risk.

Karen Wilson, CEO of GreenLab: “GreenLab is eager to work with Ginkgo on this novel go-to-market strategy. By using Ginkgo Plant Trait Services, Protein Services and Deployment Capabilities we will be able to satisfy the demand for brazzein in the market with less risk using Ginkgo’s success based pricing model. Our existing partnership with Ginkgo has enabled this unique R&D approach for a product (brazzein) that the market desperately wants.”

Sneha Srikrishnan, Senior Director of Business Development and Product Lead, Proteins, at Ginkgo Bioworks: “Our existing relationship with GreenLab has had many positive outcomes, so it made sense to continue working together! We’re thrilled to build upon our partnership and get started on this new program.”

Brennan Duty, Senior Director of Business Development and Product Lead, Plant Traits, at Ginkgo Bioworks added: “Together, we aim to unlock the full potential of brazzein and help create healthier alternatives to traditional sweeteners. We look forward to getting to work and combining Ginkgo’s expertise in protein expression and optimization in plants and microbes alike with GreenLab’s innovative approach to plant biotechnology.”

Learn more about Ginkgo’s Plant Trait Services, Protein Services, and Deployment Capabilities.

Year in Review: New Partnerships and Offerings in Agriculture in 2023

For Ginkgo, 2023 has been a banner year for serving companies leading innovation in agriculture. We’re grateful to be working with partners who are developing safe, efficacious, and consistent products for growers around the globe. Here’s our year in review.

Grateful to work with innovative partners

On the heels of expanding our ag biologicals R&D footprint and team, we entered a partnership with Syngenta, applying our encapsulation and screening technology (EncapS) to help them identify improved leads for novel plant traits. Learn more about our EncapS technology in this 5-minute video.

In addition to supporting novel traits, we also signed partnerships aimed at improving some of our partners’ existing products. These R&D programs aim to drive important commercial outcomes for our partners: strengthening their position in the biologicals market with higher-performing products or accessing greater market share by reducing unit costs of production. Read more about these collaborations:

  • AgBiome leverages our Rapid Strain Optimization services to improve product performance
  • Exacta Biosciences taps our fermentation optimization and formulation capabilities to drive down COGS of their biostimulant product, FitoRoot®
  • OneOne Biosciences will work with Ginkgo for in vitro and in planta assays to test OneOne’s Livepods™ product delivery concept. In a second phase, Ginkgo’s Rapid Strain Optimization services will aim to provide optimized strains for nitrogen fixation.

We’re thrilled to be partnering with Agrivalle to help strengthen their position in Brazil’s fast-growing ag biologicals market. Agrivalle has tapped us to be their innovation partner; we’re excited to bring our full spectrum of R&D capabilities to deliver higher performing biologicals and develop novel products that complement their existing portfolio.

And we couldn’t be more excited about our continuing partnership with Bayer, of course.

New service offerings for biologicals and traits

This year, we launched a suite of services for ag biologicals and plant traits innovators.

Our Product Headstarts aim to de-risk the early discovery part of new product development. Each Product Headstart comprises a set of strains that have undergone in silico, in vitro, and in some cases, in planta characterization focused on a specific product application. Even for partners that turn to in-licensing for portfolio growth, Product Headstarts offer the advantage of choice – partners work with Ginkgo to steer product specifications including application method and formulation. As innovation partners we work in tandem to set the standard for efficacy and consistency.

We launched our Rapid Strain Optimization services for ag biologicals this year, and both Agrivalle and AgBiome are utilizing these services to provide growers with better performing biologicals – up to 5x improved performance – using methods that are favored by regulators worldwide. Learn more about our proprietary technology underpinning this service offering in this recording of our Rapid Strain Optimization virtual event.

Novelty is key when it comes to developing plant traits. Ginkgo’s proprietary metagenomic database, our machine-learning guided protein design and optimization capabilities and our ultra-high throughput screening technologies underpin our Plant Trait services.

Contact us to learn more about these services.

Looking forward to next year

Next year, we’ll be launching new service offerings for biochemical production through fermentation. Naturally-secreted metabolites have tremendous potential as crop protection and nutrient use inputs. Many of these molecules can be produced by fermentation-friendly microbes. What’s more, this production method often enjoys wider regulatory acceptance as compared to whole microbial biologicals.

Ginkgo’s platform offers a range of unique benefits to help partners scale up biochemical production. First, we’ve optimized chassis strains with high flux across a range of small molecule classes: aromatics, terpenes, organic acids, amino acids – starting points for biochemistry that can impact crop protection and nutrition. Second, our pathway optimization and metabolic engineering capabilities lean on heavily automated workflows and troves of proprietary data relating gene sequences to function and structure.

If you’re curious about these services now, don’t hesitate to contact us using the form below!

We’re also excited to meet ag biologicals leaders and plant traits developers at conferences next year. Let us know if you’ll be attending any of the World Agritech conferences, ABIM or other great meetings in 2024!

What will you grow in 2024?

Advancing OneOne Biosciences’ Platform and Nitrogen Fixation Microbial Product

Today we’re thrilled to announce our partnership with OneOne Biosciences, a French startup building a comprehensive suite of agricultural microbial solutions for farmers!

This collaboration will leverage our robust ag biologicals infrastructure, biotechnological expertise, and Strain Optimization Services to accelerate OneOne’s research and product development in agricultural microbial solutions.

OneOne’s mission is to equip growers with bio-based agricultural inputs characterized by both exceptional effectiveness and longevity. Central to this mission is OneOne’s development of a novel, universal solution for production and delivery of ag microbials through the OneOne Multiplier™, a user-friendly “espresso machine-type” device that amplifies microbes at the point of use. Users can insert OneOne Livepods™ into the Multiplier to aseptically prepare microbials, which can then be applied directly to crops. Livepods are designed to come loaded with microbes that are tailored for specific-use cases — e.g. nitrogen fixation, phosphate solubilization, crop protection, drought resistance, carbon sequestration, and more. This fresh approach, combined with other species-independent innovative components, aims to be forward compatible with future data-based product personalization, parametrized by individual crop and soil characteristics.

OneOne’s initial focus is on developing a Livepod for nitrogen fixation, a roughly $100 billion market. OneOne will work with Ginkgo for in vitro and in planta assays to test OneOne’s concept. In a second phase, Ginkgo plans to use its Strain Optimization Services and ultra high throughput encapsulated screening to provide optimized strains for nitrogen fixation. The strains may then progress to field trials and regulatory preparations before commercialization.

“We are building a platform to provide growers with a complete range of microbial solutions beneficial to their crops, soils, and bottom lines. We expect our products to maximize long-term agronomic performance and farmer ROI. We are excited by this strategic partnership with Ginkgo, as we believe they are the only player capable of bringing all the expertise, infrastructure, and experience needed to ensure effective and efficient handling of key lines of our ag biologicals research and product development. We are confident that Ginkgo’s comprehensive services can generate valuable strain assets and reduce time-to-market. We look forward to contributing to the ongoing transition from chemicals towards bio-based solutions in the agricultural space, as is happening in other large industries. We expect that, at scale, this transition can and will drive significant net positives for economies and the environment in years to come.”

OneOne’s founder and CEO, Julien Sylvestre

Our partnership underscores the growing role of synbio in agriculture.

We’re thrilled to assist OneOne in demonstrating their concept and to apply our deep experience with nitrogen fixation as we seek to deliver successful strains for their Livepods. We firmly believe ag biologicals represent the future of sustainable, successful agriculture, and we are eager to support innovators like OneOne in entering the market with cutting-edge solutions.

We are also so excited to welcome OneOne’s founder and CEO, Julien Sylvestre, to the stage at our Ferment 2024 conference!

You can learn more about Ferment 2024 here!

To learn more about Ginkgo Strain Optimization Services, please visit https://www.ginkgobioworks.com/offerings/strain-optimization-services

What will you grow with Ginkgo?

Accelerating Next-Gen Ag Biological Products with Agrivalle

We’re thrilled to announce our new partnership with Agrivalle, a leading Brazilian agricultural biologicals company!

Together, we plan to build cutting edge technologies that can advance Agrivalle’s biological products, including next-gen fertilizers and biocontrol agents.

Ginkgo is bringing its suite of advanced biology tools to this partnership.

Our Strain Optimization Services will be leveraged to improve the efficacy of Agrivalle’s biocontrol products. In planned future projects, we intend to work with Agrivalle to discover and optimize plant-compatible microbes that can provide crop nutrition, and to engineer organisms that can make compounds to specifically target certain pests. This, in turn, could help Agrivalle enhance the breadth and efficacy of their novel biological products and enable them to sell and license products to major players in agriculture across the globe.

Growers continue to have an increased need for effective and sustainable alternatives to pest control products.

Brazil has been home to massive growth in biologicals, thanks in part to regulatory frameworks that encourage innovation in the development of biologicals for sustainable agriculture. The Brazilian government has also made it easier for startups to finance manufacturing plants and to register biological products. This has led the country to become the largest biologicals market for agriculture, growing over 30% a year.

We are so excited to partner with Agrivalle on getting groundbreaking biological products into the hands of growers. Agrivalle is a vanguard of innovation in Brazil with proven R&D, manufacturing, and sales prowess, and we’re thrilled to help them optimize and advance their products as they seek to expand globally.

“Choosing Ginkgo as a strategic partner will enable Agrivalle products to be at the forefront of agricultural excellence. Having access to Ginkgo’s demonstrated technical capabilities and expertise in biologicals R&D will help us take our products to the next level and support growers who seek superior bio-based technology.”

André Kraide, CEO of Agrivalle

To learn more about Ginkgo Strain Optimization Services, please visit https://www.ginkgobioworks.com/offerings/strain-optimization-services/.

AgBiome Leverages Ginkgo Strain Optimization Services

Today we’re announcing a partnership with AgBiome, a leader in global microbial innovation.

The aim is to optimize the performance of products in AgBiome’s pipeline of agricultural biologicals. Organizations developing next generation agricultural inputs can access our platform to accelerate discovery and deployment of new products.

By leveraging Ginkgo’s Strain Optimization Services, AgBiome aims to provide growers with new and improved live microbial strain products.

The biological crop protection market has significantly grown in recent years. Growers have increasingly sought effective and sustainable alternatives to synthetic pest control products. By leveraging our suite of advanced biology tools, AgBiome aims to enhance the breadth and efficacy of novel biological products.

We believe we can identify improved variants at massive scale.

That can help deliver more potent agricultural biologicals and bring the next generation of products to market. We are thrilled to work with an industry leader like AgBiome as we seek to optimize live microbial strain products in their pipeline and provide even better solutions to growers around the world.

“AgBiome is committed to creating the most effective crop protection products, and we are always looking for new technologies to enable better performance. We are excited to utilize Ginkgo’s capabilities in ultra high throughput assay development to evolve the next generation of biologicals as we continue to provide growers with improved product efficacy.”

-Scott Uknes, Co-founder and Co-CEO of AgBiome

Ginkgo’s ultra high throughput encapsulated screening technology:

  • Makes it possible to search through up to 1 million strain variants in a single run
  • Selects the best performing candidates for further development
  • Is built on nanoliter encapsulation technology, and thus provides nanoscale growth and assay compartments
  • Makes it possible to greatly reduce the screening time for large libraries

 

Find the full press release here along with all of the latest news from the Ginkgo team.

What will you grow with Ginkgo?

Optimizing Enzyme Expression and Performance with Zymtronix

Optimizing enzymes for Zymtronix’s cell-free manufacturing platform

Today we are pleased to announce our partnership with Zymtronix, a developer of cell-free process technologies. Together we aim to optimize enzymes used in Zymtronix’s proprietary cell-free platform for the production of important ingredients in food, agriculture, cosmetics and pharmaceuticals.

Enzymatic biocatalysis is a powerful manufacturing technology that can enable the production of a wide range of chemicals and molecules. Zymtronix’s cell-free platform is designed to solve challenges associated with traditional biocatalysis and seeks to enable the production of a wide range of products with precision and productivity. By partnering with us to build and produce bioengineered market-ready enzymes, Zymtronix anticipates being able to extend its solutions into the pharma, nutrition, agriculture markets, among others.

Zymtronix aims to leverage Ginkgo Enzyme Services to discover, optimize, and produce enzymes

Ginkgo Enzyme Services offers partners end-to-end support for the discovery, optimization, and production of enzymes for diverse applications. Through the partnership, we will leverage our suite of enzyme services to engineer enzymes for Zymtronix’s applications using metagenomic enzyme discovery as well as improve enzyme expression and production host performance.

We’re thrilled to welcome Zymtronix to the platform and support their applications in sustainable ingredients and beyond. We’ve built out our platform to serve a wide variety of enzyme discovery, engineering, optimization and scale up efforts, and we’re so excited for the work to come in this partnership. Zymtronix’s cell-free biomanufacturing platform is pioneering solutions for various industries, and we’re eager to leverage our end-to-end capabilities and help expand its efforts in transforming the way enzymes are used.

“This partnership will greatly accelerate our work of bringing the precision and scalability of cell-free biomanufacturing and sustainable ingredients to market starting with alternatives to animal sources; Ginkgo is uniquely able to support us with both enzyme engineering and strain expression, helping us continue to accelerate commercialization,” said Stéphane Corgié, CEO-CTO and founder, Zymtronix. “We hope to extend this partnership in the future to facilitate the production of multiple end-market products.”

To learn more about Ginkgo Enzyme Services, please visit ginkgobioworks.com/enzyme-services/.

Find the full press release here along with all of the latest news from the Ginkgo team.

What will you grow with Ginkgo?

Revolutionizing Enzyme Engineering: The Synergy of Big Data and AI at Ginkgo Bioworks

 

Enzyme Engineering and Artificial Intelligence

A new frontier

Enzymes are the heroes of biotechnology, serving as biological catalysts that make life’s complex reactions look easy. Inside of the cell, enzymes direct the flow of molecules through metabolic pathways, orchestrating biological functions. Outside of their cellular context, enzymes have been co-opted for specialized roles in manufacturing, speeding up processes that would otherwise be painstakingly slow. In pharmaceuticals, enzymes are custom-engineered to act as targeted therapeutics. Whether in life sciences or industrial applications, enzymes elevate our ability to engineer processes and enact chemistries by facilitating reactions with speed and specificity.

For years, scientists have used a variety of tools to design and optimize these crucial biological components. Traditional methods have often hinged on exploiting evolutionary pressures—letting nature do the heavy lifting over generations and then picking the winners. Structure-based prediction techniques, like Rosetta, also made a significant impact, allowing researchers to model how tweaks to an enzyme’s structure could influence its activity.

But we’re entering a new era–one in which we can train Artificial Intelligence (AI) models based on large biological data sets. This is where Ginkgo Bioworks comes in. Our expansive cell engineering platform is a data-generating powerhouse, churning out the kind of high-quality, voluminous data that AI algorithms thrive on. The marriage of this large-scale data generation with AI models allows us to transcend previous limitations, making Ginkgo an ideal environment to train and deploy machine learning tools for the complex art of enzyme engineering.

The AI Story

Big data, bigger breakthroughs

AI learns from large data sets. Ginkgo Bioworks generates these types of data: we make it possible for you to produce and learn from large data sets. Our extensive repositories of enzymes not only cover a wide range of protein sequences but are also complemented by highly targeted data, revealing precise sequence-function correlations. This dual-data approach is implemented through machine learning cycles in our enzyme engineering projects, enabling us to iteratively refine predictive models.

Ginkgo has developed an AI tool, Owl, to fine-tune enzymes for a specialized role. An expansive data set provides the foundational architecture. To construct the intricate details, however, we employ data that is calibrated to the specific enzyme and its intended function. This enables Owl, our machine learning tool, to not merely “learn” but to “apply” its learnings, writing the intricate, detailed novel enzyme that our scientists require. Owl can “see in the dark” and discern viable paths in complex enzyme design landscapes.

Ginkgo’s approach to enzyme design isn’t merely data accumulation; it’s strategic data deployment. Our Foundry is equipped to generate an extensive range of high-quality biological data at scale. From DNA design and synthesis to high-throughput screening, we create vast data sets corroborating structure-function relationships. Owl thrives in this environment, allowing us to design enzyme variants tailored to our partners’ unique specifications, whether that’s enzyme activity, specificity, or other parameters.

As we navigate the complexities of enzyme design and optimization, think of Owl as the expert navigator and our robust data sets and data-generating capabilities as the compass and map. Together, they form a symbiotic alliance that not only challenges but also redefines the boundaries of traditional R&D.

Tackling Enzymes in Central Carbon Metabolism

The power of iteration and integration

Enzymes that regulate flux through Central Carbon Metabolism (CCM) are biological masterpieces. These proteins have been shaped by billions of years of evolutionary refinement to execute their functions with unmatched precision and, in many cases, maintain high sequence and structure conservation throughout the tree of life.

In one example of Owl-guided enzyme optimization, we were asked to improve the reaction kinetics of an enzyme involved in CCM. While this enzyme had been studied for the past 50 years, the best improvement we found in the literature was a 2-fold increase in the kcat/KM–catalytic efficiency; our customer needed a 10-fold improvement in the efficiency of this enzyme in order to meet their economic targets.

Our approach to this project leveraged our Foundry’s ability to generate and test large libraries of strains. In our initial data-generation phase, we created a first-generation library featuring 2,000 distinct enzyme variants crafted using a structure-based design, as well as semi-rational methods like active-site mutagenesis for targeted alterations. This is an important step because it generated a data set for initial Owl training. With this information in hand, we designed a second generation library to give Owl more information: we maintained the library size of the first but incorporated insights from the previous round, resulting in an exciting 3.9-fold improvement—a leap that surpassed anything we had seen before.

But the real improvements were just beginning. The third generation of this program brought us to a pivotal point in our optimization journey. Leveraging Owl’s predictive analytics, we strategically developed a broad library of 4,000 enzyme variants, generating diversity where it mattered most. The result was an unprecedented 4.5-fold improvement in enzyme efficiency, serving as a testament to Owl’s growing mastery in predictive capability.

Data from these three consecutive generations positioned us to make our biggest improvements yet. Given the data that our scientists had generated, Owl continued to generate increasingly sophisticated models of enzyme function. The final iteration culminated in a fourth generation where only 100 enzyme variants needed to be tested. The result, which marked the successful completion of this customer program, was astonishing: a 10-fold improvement in enzyme function, verified through meticulous arrayed activity assays and detailed protein characterization. By integrating the large data sets generated by Ginkgo’s cell engineering platform with Owl’s predictive power, we surpassed the bounds of natural evolution and decades of research reported in the literature meet our customer’s targets.

The Future of Enzyme Engineering

Large data and machine learning at Ginkgo Bioworks

The confluence of big data and AI accelerates the pace of innovation to unprecedented speeds. Ginkgo’s cell engineering platform is an ecosystem designed for generating expansive, high-quality data sets customized for complex biological inquiries. This data, in turn, fuels the predictive power of AI models. Together, they form a symbiotic relationship that enables us to challenge the limitations of natural evolution and traditional research methods.

As stakeholders in the biotechnology industry, navigating complex R&D challenges requires more than just robust tools; it requires effective partnerships. Ginkgo Bioworks offers the specialized machine learning models and data-generation capabilities necessary to advance your research and overcome bottlenecks. Our suite of resources is designed to integrate seamlessly with your objectives, providing actionable insights and solutions tailored to your specific challenges.

Ginkgo is investing in the future of AI for biotech: see our recent announcement with Google about developing foundation generative AI models for DNA and protein. Leverage our expertise and technology for your next project, and to join us in pushing the boundaries of what is possible in synthetic biology.


Expanding Our Platform Capabilities in Agricultural Biologicals and Launching Flagship Partnership with Bayer

Announcement Highlights:

  • Planned transaction expands Ginkgo’s horizontal platform capabilities to support agricultural biologicals R&D from discovery through formulation and early field trials and will offer services to allow access to customers of all sizes in the agriculture industry
  • Under the proposed transaction, Ginkgo to acquire Bayer’s West Sacramento agricultural biologicals site and team, adding a 175,000 square-foot R&D facility with pilot scale fermentation, formulation, and greenhouse facilities, along with access to Bayer’s large agricultural strain collection
  • Joyn Bio, the joint-venture between Ginkgo and Leaps by Bayer formed in 2017, to be integrated into the parent companies, with the core technology platform becoming part of Ginkgo’s platform and key products being advanced by Bayer in a new collaboration
  • Bayer to be an anchor customer of Ginkgo’s agricultural biologicals offering, signing a follow-on multi-year platform collaboration deal to enable continued development of Joyn Bio’s flagship nitrogen fixation program and launching new programs in fields including next-generation crop protection and carbon sequestration

We’re excited to announce plans to significantly expand our platform capabilities in agricultural biologicals from discovery to field. These capabilities will be built through a series of transactions; Ginkgo will acquire Bayer’s 175,000 square-foot West Sacramento Biologics Research & Development site, team, and internal discovery and lead optimization platform. Ginkgo will also integrate the R&D platform assets from Joyn Bio, a joint-venture between Ginkgo and Leaps by Bayer formed in 2017. Bayer will be the anchor agricultural customer of Ginkgo’s expanded platform, entering into a significant new multi-year collaboration which will focus on the advancement of Joyn’s marquee nitrogen fixation program as well as new programs in areas such as crop protection and carbon sequestration.

While Ginkgo will continue to evaluate the operating expenditures required to launch and scale its expanded agricultural capabilities following these transactions, it is expected that the cash proceeds from this multi-year collaboration with Bayer may significantly offset such anticipated expenditures. The proposed transactions are projected to close before the end of 2022, pending the finalization of definitive agreements and subject to regulatory approvals.

Agricultural biologicals are a rapidly growing category of solutions that offer tremendous sustainability and performance benefits. Against the backdrop of rising fertilizer costs and novel pest and disease threats, growers are calling for new agriculture solutions that can increase yields while decreasing their environmental footprint. While chemical and plant trait solutions have long been the dominant solutions on the market, demand for biologicals has increased dramatically.

Bayer, Ginkgo, and Joyn share a common vision, which is to enable biological products to be a critical part of the solution to the world’s greatest agricultural and environmental challenges. We are incredibly impressed by the success of the Joyn team and the deep expertise of Bayer’s West Sacramento R&D team and are thrilled to have them join Ginkgo as we build deep end-to-end capabilities in ag biologicals on top of our large scale horizontal platform. We believe we’re bringing together the most innovative minds in agriculture with the experience of a team that has brought several effective biological products to market for Bayer — opening this platform up to the world has the potential to truly revolutionize the field.

Bayer has long been committed to expanding its product offerings to benefit growers around the world. In recent years, the company has made a strategic decision to focus on becoming the preferred research, development, and commercial partner in the biologicals segment, while leveraging an “open innovation” model to be able to partner broadly with disruptive discovery companies.

Through this agreement, Bayer is committing to a significant multi-year collaboration, advancing multiple programs including a marquee nitrogen fixation program as well as a suite of other programs in areas such as next-generation crop protection and carbon sequestration.

“Biological solutions will play a critical role in the agricultural innovation ecosystem, and we see tremendous opportunity for biologicals to add even more value for agriculture in the future because they are effective and offer environmental benefits that producers want,” said Bob Reiter, Head of R&D for Bayer Crop Science. “Bayer is moving to strengthen its product development and commercial positioning through strategic research partnerships for new product development, and we are excited to deepen our relationship with Ginkgo, which we expect to be a key partner for many years to come.”

Over the last five years, Joyn has developed a new class of microbial solutions in partnership with Bayer and Ginkgo. Through this transaction, Joyn’s product concepts will be advanced by Bayer, with a particular focus on its nitrogen fixation program, while the platform assets and supporting team members will be integrated into Ginkgo as the company expands its support for agricultural biologicals.

Ginkgo will offer these new platform capabilities to a wide variety of customers in the agriculture space.

Ginkgo expects to provide a full stack of services in this field. This extension of our platform will allow companies of all sizes to access best-in-class lab-to-field translation expertise, greenhouse capacity, formulation capabilities, and pilot fermentation.

“With support from Ginkgo and Bayer, Joyn Bio has made groundbreaking discoveries across a number of programs that will be foundational for future work in biologicals,” said Michael Miille, CEO of Joyn Bio. “We are excited to take this platform to the next stage, with Bayer advancing key programs to the next level and working with Ginkgo to open our capabilities up to a broader set of commercial partners.”

The parties expect to sign a definitive agreement and proceed toward an efficient close, supported by ongoing integration planning efforts. More details and updates will be provided when available.

Find the full press release here along with all of the latest news from the Ginkgo team.

Optimizing the Brightness of Glowing Plants with Light Bio

Leveraging Ginkgo’s engineering capabilities to optimize performance of Light Bio’s light-emitting plants

We’re excited to announce a new collaboration with Light Bio – a company creating bioluminescent plants for home and garden. The agreement will leverage Ginkgo’s plant cell assays for bioluminescence engineering. The aim: to improve the luminescent output and efficiency of the enzymes within Light Bio’s glowing ornamental plants.

Nothing captures the wonder of biology quite like seeing glowing plants in person. Our platform enables developers to imagine with biology and to design all types of cells, from bacteria and yeast to mammalian and plant cells. We’re so excited to bring this unique application onto our platform and to help Light Bio bring the magic of glowing plants to people.

Light Bio has discovered a new type of bioluminescence mechanism and uses synthetic biology to engineer plants to efficiently emit light. The original light emission pathway Light Bio uses in its glowing plants comes from bioluminescent mushrooms. The company is now focused on expanding its engineering capabilities to support the creation of glowing plants.

“We are excited to collaborate with Ginkgo toward additional multifold output and efficiency improvements powered by Ginkgo’s plant cell engineering capabilities across both individual enzyme and metabolic pathway improvements,” said Keith Wood, CEO, Light Bio.

What will you grow with Ginkgo?

New Platform Venture: Launching BiomEdit

BiomEdit intends to leverage Ginkgo’s platform to discover and develop microbiome-based animal health products to improve animal health, animal protein production, and livestock disease monitoring.

We’re excited to announce the launch of BiomEdit, a microbiome innovation company that is expected to discover, develop, and introduce novel probiotics, bioactive molecules, engineered microbial medicines and microbial monitoring services for animal health.

Microbiome science is a rapidly growing field creating breakthroughs in animal health based on the microbial communities that live in animals and their surrounding environment. BiomEdit intends to discover, develop and introduce differentiated products that address some of the greatest needs for innovation in animal health, including medicated feed ingredients, nutritional health and therapeutics for livestock and pet species, as well as biosecurity technology for animal disease monitoring.

BiomEdit is Ginkgo’s latest platform venture, created in partnership with Elanco Animal Health — a leading global animal health company.

In October 2021, Elanco announced its intention to carve out its microbiome platform and pipeline under the leadership of Aaron Schacht, BiomEdit CEO and former Elanco executive vice president of Innovation, Regulatory and Business Development, to concentrate and focus more resources on its high value late-stage Pet Health pipeline. BiomEdit is the result of this separation, and was developed with Ferment Co., the company creation studio that helps ideate and launch new companies across a variety of end-markets that use cell programming to support human and environmental health and well-being.

Elanco will contribute intellectual property and a pipeline of ongoing programs to BiomEdit, which will be staffed with members of the former Elanco microbiome R&D team. The team brings the expertise and experience needed to build on the foundation of microbiome work started at Elanco. By leveraging foundational programs from Elanco, intellectual property from both Elanco and Ginkgo, and an experienced team, BiomEdit should be well positioned as a stand-alone company to develop and launch innovative products to address unmet needs in animal health.

“Livestock producers and veterinarians are calling for new products that address antibiotic resistance and improve livestock sustainability,” said Mr. Schacht. “Coupling the platform, pipeline and deep expertise of the former Elanco microbiome team with Ginkgo’s unique screening and strain engineering capabilities will accelerate and amplify our ability to advance novel animal microbiome inspired products for animal health.”

“Elanco is excited to continue its participation in the microbiome by partnering with Ginkgo, Viking Global Investors and Anterra Capital to create the next-generation animal health innovation player,” said Jeff Simmons, president and CEO of Elanco Animal Health. “We wish Aaron and his team the best as they build out this novel innovation platform to address unmet needs in animal health, such as alternatives to antibiotics.”

Ginkgo has significant expertise in the discovery, design and monitoring of microbes at scale for a wide array of functions.

BiomEdit plans to leverage Ginkgo’s state-of-the-art cell programming platform to improve the design and development of probiotics, bioactives, engineered microbial medicines, and microbial monitoring services. BiomEdit joins other Ginkgo platform ventures such as Joyn Bio, Motif FoodWorks, Allonnia, Arcaea, Verb Biotics and Ayana Bio.

We are always on the lookout for opportunities to accelerate our partners’ abilities to address massive challenges, such as antibiotic resistance in livestock. Together, we see Ginkgo and BiomEdit addressing significant opportunities in the animal health industry with new breakthroughs based on microbiome science. We deeply depend on the health of animals in our ecosystem and supply chains; the potential applications for our cell programming platform in this area are far reaching.

In addition to the assets and intellectual property contributed by Elanco and Ginkgo, BiomEdit is launching with a targeted Series A funding raise of $40 million, with participation by Viking Global Investors and Anterra Capital. In exchange for their respective asset and intellectual property contributions, Elanco and Ginkgo are expected to retain approximately 40% combined proportional ownership of BiomEdit, on a fully-diluted basis, upon the completion of the Series A financing. Elanco’s ownership will be in non-voting shares.

J.P. Morgan Securities LLC acted on behalf of Elanco as sole placement agent on the financing.

Find the full press release here along with all of the latest news from the Ginkgo team.